BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ii-Key/HER2/neu cancer vaccine: Phase II data

A single-blind Phase II trial in 102 high-risk breast cancer patients showed that AE37 plus granulocyte macrophage colony-stimulating factor (GM-CSF) given sequentially or concurrently with Herceptin...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >